A Study of FG-3019 in Subjects With Liver Fibrosis Due to Chronic Hepatitis B Infection
Status:
Terminated
Trial end date:
2015-06-01
Target enrollment:
Participant gender:
Summary
The overall goal of this trial is to evaluate the efficacy of FG-3019 for reversing liver
fibrosis in subjects with chronic hepatitis B infection who are beginning antiviral therapy
with entecavir. This Phase 2 randomized, double-blind, placebo controlled study will enroll
subjects with chronic active hepatitis B infection and liver fibrosis (Ishak score ≥2) who
are eligible for antiviral therapy.